Literature DB >> 2016708

2-aralkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor.

M Ueeda1, R D Thompson, L H Arroyo, R A Olsson.   

Abstract

A Langendorff guinea pig heart preparation served for the assay of agonist potency of a series of 26 2-aralkoxyadenosines at the A1 and A2 receptors of, respectively, the atrioventricular node (conduction block) and coronary arteries (vasodilation). All of the analogues are weak agonists at the A1 receptor, requiring concentrations greater than 9 microM to cause second degree heart block. At the A2 receptor 2-phenethoxyadenosine is the most potent of the 2-phenylalkyladenosines. The activity of ring-substituted (F, Cl, CH3, and OCH3) 2-phenethoxyadenosines increases ortho less than meta less than para. The EC50s of coronary vasoactivity of several para-substituted analogues are in the subnanomolar range. The most potent analogue, 2-[2-(4-methylphenyl)ethoxy]adenosine 19, has an EC50 for coronary vasodilation of 190 pM and an A1/A2 selectivity ratio of 44,000. Aryl groups such as thienyl, indoloyl, or naphthyl also support A2 agonist activity. Although 2-oxoadenosine is 3 times more vasoactive than 2-aminoadenosine, the activities of the phenyl derivatives are markedly different; 2-phenoxyadenosine is 23 times weaker than 2-(phenylamino)adenosine (CV-1808).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2016708     DOI: 10.1021/jm00108a015

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A2A receptor.

Authors:  A P IJzerman; E M van der Wenden; P J van Galen; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1994-06-15       Impact factor: 4.432

2.  Cloning and expression of the A2a adenosine receptor from guinea pig brain.

Authors:  F Meng; G X Xie; D Chalmers; C Morgan; S J Watson; H Akil
Journal:  Neurochem Res       Date:  1994-05       Impact factor: 3.996

3.  The role of adenosine in the early respiratory and cardiovascular changes evoked by chronic hypoxia in the rat.

Authors:  Martin P Walsh; Janice M Marshall
Journal:  J Physiol       Date:  2006-05-11       Impact factor: 5.182

4.  Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel).

Authors:  Cassandre Victor-Vega; Avani Desai; M Carmen Montesinos; Bruce N Cronstein
Journal:  Inflammation       Date:  2002-02       Impact factor: 4.092

5.  Inhibition of platelet aggregation by adenosine receptor agonists.

Authors:  G Cristalli; S Vittori; R D Thompson; W L Padgett; D Shi; J W Daly; R A Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-06       Impact factor: 3.000

6.  Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists.

Authors:  K A Jacobson; C Gallo-Rodriguez; N Melman; B Fischer; M Maillard; A van Bergen; P J van Galen; Y Karton
Journal:  J Med Chem       Date:  1993-05-14       Impact factor: 7.446

7.  2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors.

Authors:  Zhan-Guo Gao; Liaman K Mamedova; Peiran Chen; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2004-11-15       Impact factor: 5.858

Review 8.  Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.

Authors:  K A Jacobson; P J van Galen; M Williams
Journal:  J Med Chem       Date:  1992-02-07       Impact factor: 7.446

Review 9.  Adenosine A1 and A2 receptors: structure--function relationships.

Authors:  P J van Galen; G L Stiles; G Michaels; K A Jacobson
Journal:  Med Res Rev       Date:  1992-09       Impact factor: 12.944

Review 10.  Adenosine: Synthetic Methods of Its Derivatives and Antitumor Activity.

Authors:  Francisco Z Valdés; Víctor Z Luna; Bárbara R Arévalo; Nelson V Brown; Margarita C Gutiérrez
Journal:  Mini Rev Med Chem       Date:  2018       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.